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Abstract
The transcription factor FOXP1 is implicated in the pathogenesis of B-cell lymphomas through chromosomal translocations
involving either immunoglobulin heavy chain (IGH) locus or non-IG sequences. The former translocation, t(3;14)(p13;q32),
results in dysregulated expression of FOXP1 juxtaposed with strong regulatory elements of IGH. Thus far, molecular
consequences of rare non-IG aberrations of FOXP1 remain undetermined. Here, using molecular cytogenetics and molecular
biology studies, we comprehensively analyzed four lymphoma cases with non-IG rearrangements of FOXP1 and compared
these with cases harboring t(3;14)(p13;q32)/IGH-FOXP1 and FOXP1-expressing lymphomas with no apparent structural
aberrations of the gene. Our study revealed that non-IG rearrangements of FOXP1 are usually acquired during clinical course
of various lymphoma subtypes, including diffuse large B cell lymphoma, marginal zone lymphoma and chronic lymphocytic
leukemia, and correlate with a poor prognosis. Importantly, these aberrations constantly target the coding region of FOXP1,
promiscuously fusing with coding and non-coding gene sequences at various reciprocal breakpoints (2q36, 10q24 and
3q11). The non-IG rearrangements of FOXP1, however, do not generate functional chimeric genes but commonly disrupt
the full-length FOXP1 transcript leading to an aberrant expression of N-truncated FOXP1 isoforms (FOXP1NT), as shown by
QRT-PCR and Western blot analysis. In contrast, t(3;14)(p13;q32)/IGH-FOXP1 affects the 59 untranslated region of FOXP1 and
results in overexpress the full-length FOXP1 protein (FOXP1FL). RNA-sequencing of a few lymphoma cases expressing
FOXP1NT and FOXP1FL detected neither FOXP1-related fusions nor FOXP1 mutations. Further bioinformatic analysis of RNA-
sequencing data retrieved a set of genes, which may comprise direct or non-direct targets of FOXP1NT, potentially
implicated in disease progression. In summary, our findings point to a dual mechanism through which FOXP1 is implicated
in B-cell lymphomagenesis. We hypothesize that the primary t(3;14)(p13;q32)/IGH-FOXP1 activates expression of the
FOXP1FL protein with potent oncogenic activity, whereas the secondary non-IG rearrangements of FOXP1 promote
expression of the FOXP1NT proteins, likely driving progression of disease.
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Introduction
The FOXP1 (Forkhead box P1) gene located at 3p13 (previously
assigned to 3p14.1) codes for a transcriptional regulator belonging
to the FOX transcription factor family which is implicated in a
wide range of biological processes [1,2]. Multiple alternative
splicing variants of FOXP1 have been annotated (www. ensem-
ble.org). The FOXP1 protein is widely expressed in human tissues.
It harbors an N-terminal poly-Gln region, C2H2-type zinc finger
and leucine zipper motifs, and a C-terminal DNA binding
forkhead or winged helix domain [3]. FOXP1 is an essential
factor in cardiac, lung, neural, monocyte and lymphocyte
development and maturation, stem cell biology and in immune
responses [4–14]. Multiple lines of evidence indicate that FOXP1
plays an important role in tumorigenesis [15]. Initial studies of
Banham et al. [16] suggested that FOXP1 acts as a tumor
suppressor in epithelial malignancies recurrently characterized by
D3p13p14/FOXP1 and loss or decreased expression of the FOXP1
protein. Very recent work of Krohn et al. [17] on prostate cancers
supports this concept. Interestingly, subsequent studies postulated
an oncogenic role of FOXP1 in lymphoma, particularly in an
activated B-cell subtype of diffuse large B-cell lymphoma (ABC-
DLBCL) with a poor clinical outcome [18–23], and extranodal
marginal zone lymphoma (MZL), where a strong expression of
FOXP1 protein correlates with a risk of a high grade transforma-
tion [24–27]. Further investigations showed that FOXP1-positive
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ABC-DLBCL [28], as well as follicular lymphoma [29] and
primary central nervous system lymphoma [30], preferentially
express shorter FOXP1 isoforms, which in non-malignant
conditions, may be induced by B-cell activation [28]. It has been
hypothesized that the role of FOXP1 as oncogene is due to
expression of short FOXP1 isoforms, while the full length FOXP1
(FOXP1FL) acts as tumor suppressor [15,28].
Noteworthy, FOXP1 is targeted by rare but recurrent chromo-
somal translocations in lymphoma, particularly MZL and DLBCL
[31–35]. The most frequent is t(3;14)(p13;q32), which brings the
gene under the regulatory control of the immunoglobulin heavy
chain (IGH) locus at 14q32 [31,34]. Other FOXP1 translocations
involve non-IG sequences; the molecular consequences of these
aberrations, however, remain undetermined [32,33,35].
In the reported study, we performed genetic and molecular
analysis of four lymphoma cases with non-IG translocations of
FOXP1 and compared these with cases harboring
t(3;14)(p13;q32)/IGH-FOXP1 and DLBCLs with a strong expres-
sion of FOXP1 and with no apparent structural aberrations of the
gene (FOXP1-positive DLBCL). Our study demonstrates that
non-IG rearrangements of FOXP1 do not generate chimeric
transcripts but activate an aberrant expression of transcriptional
variants of FOXP1 and N-terminally truncated FOXP1 isoforms
(FOXP1NT). In addition, our data suggest that non-IG transloca-
tions of FOXP1 are implicated in progression of various B-cell
neoplasms, including chronic lymphocytic leukemia (CLL).
Materials and Methods
Patients
Lymphoma cases with and without FOXP1 rearrangements
were selected from the database of the Center for Human Genetics
and Department of Pathology, KU Leuven, Leuven, Belgium.
One case with t(non-IG/FOXP1) was provided by Dr. E.
Haralambieva (Institute of Pathology, University of Wu¨rzburg,
Wu¨rzburg, Germany). Morphology, immunophenotype and clin-
ical records of the studied cases were reviewed. DLBCL subtyping
followed immunohistochemical (IHC) algorithm of Hans et al.
[36]. The study was approved by the institutional review board
‘‘Commissie Medische Ethiek’’ of the University Hospital. For this
retrospective study the ‘‘Commissie Medische Ethiek’’ waived the
need for written informed consent from the participants.
Cytogenetic and Fluorescence in situ Hybridization
Analysis
G-banding chromosomal analysis and fluorescence in situ
hybridization (FISH) followed routine methods. Probes applied
for FISH are listed in Table S1. Non-commercial probes were
labeled with SpectrumOrange- and SpectrumGreen-d-UTP
(Abbott Molecular, Ottigne, Belgium) using random priming.
FISH images were acquired with a fluorescence microscope
equipped with an Axiophot 2 camera (Carl Zeiss Microscopy,
Jena, Germany) and a MetaSystems ISIS imaging system
(MetaSystems, Altlussheim, Germany). One to ten abnormal
metaphases and/or 200 interphase cells were evaluated in each
experiment.
Immunohistochemistry
For routine IHC ready-to-use antisera against CD20, CD10,
BCL6 and MUM1 from DAKO (Glostrup, Denmark) were used
and stainings were performed using the automated DAKO stainer
Anti-FOXP1 antibody (ab16645) was purchased from Abcam
(Cambridge, UK) and used at dilution 1:200. We additionally used
anti-FOXP1 serum from Roche Diagnostics (SP133, Roche
Diagnostics, Vilvoorde, Belgium) and staining followed the
manufacturer’s recommendations. IHC results were visualized
using the OptiView DAB IHC Detection Kit (Ventana, Oro
Valley, Tucson, Arizona). Image acquisition was done through a
Leica microscope at 2006 and 1006magnification. Images were
assembled using Adobe Photoshop CS5.
RNA Extraction and cDNA Preparation
TRIzol LS Reagent (Invitrogen, Carlsbad, CA, USA) was used
for a total RNA extraction. cDNA was synthesized from 1 mg of
total RNA using reverse transcriptase Superscript II (Invitrogen,
Carlsbad, CA, USA) and random primer (Invitrogen, Carlsbad,
CA, USA).
Quantitative RT-PCR
QRT-PCR was performed using LC480 SYBR Green I Master
and the LightCycler 480 Real-Time PCR System. Data were
analyzed with the LC480 software (Roche Diagnostics, Indianap-
olis, IN, USA). Primers representative for exons 3–18 (Table S2)
were designed using Light Cycler Probe Design Software 2.0. CT
values were averaged for triplicate reactions and used to calculate
DCT values for each sample. HPRT1 was used as a reference gene
for normalization. RPMI-8402, a T-cell leukemia cell line (www.
dsmz.de), was used to normalize the relative expression of FOXP1
between the samples.
59-Rapid Amplification of cDNA Ends PCR (59RACE-PCR)
First strand cDNA was synthesized from 3 mg of total RNA as
previously described but using the oligonucleotide FOXP1/ex8R-
Race1 designed on exon 8 of FOXP1. The first strand cDNA was
tailed with deoxyadenosine triphosphate (dATP). Second strand
was synthesized using Klenow DNA polymerase (Promega,
Fitchburg, WI, USA) and the primers mix TV8. Anchored PCR
was performed for 35 cycles with primers FOXP1/ex7R/race-1
and 467, and for nested PCR we used the primers FOXP1/ex7R/
race-2 and 468. PCR products were cloned to pGEM-T Easy
(pGEM-T-easy Vector system I, Promega, Fitchburg, WI, USA)
and sequenced.
RT-PCR
First strand cDNA was synthesized as described above. PCR
was performed on the cDNA with the primers FOXP1/ex7R/
race-2 and PLEKHG1/forward primers to confirm the FOXP1/
PLEKHG1 fusion in case 7 (Table S2).
Western Blotting
Sections from frozen lymph node samples were lysed and
processed for Western blotting according to standard procedure
using the following antibodies: anti-FOXP1 (1:100 dilution; JC12/
ab32010; Abcam, Cambridge, UK) and anti-beta-actine (1:300
dilution; AC-15; Sigma Aldrich, St. Louis, MO, USA). Protein
detection was performed with Image Quant Las4000. The AIDA
software (Advanced Image Data Analyzer, version 4.15.025,
Raytest GmbH, Straubenhardt, Germany) was used for a
densitometric analysis of Western blots.
Library Preparation for Paired-end RNA-sequencing
The Illumina standard kit (IlluminaH TruSeqTM RNA Sample
Preparation Kit, San Diego, CA, USA) was used for the mRNA-
sequencing sample preparation according to the manufacturer’s
protocol. The quality of the libraries was checked by Agilent
Technologies 2100 Bioanalyzer, using the Chip (Agilent DNA
1000 Kit).
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Figure 1. Partial karyotypes and examples of FISH analysis performed in the index cases. The applied probes included RP11-79P21-SG
and RP11-905F6-SO (a, h), RP11-183N07-SG and RP11-56107-SO (b), FOXP1 BA (c, e, g), RP11-2F13-SO and RP11-346A7-SG (d) and CTD-2234G15-SG
and RP11-778P17-SO (f). Note split/separated FOXP1 signals in all index cases (a, c, e, g, h), split of RP11-183N07 spanning AP1S3/2q36.1 in case 1 (b),
separation of signals flanking the 10q24 breakpoint in case 2 (d) and cohybridization of CTD-2234G15/3p11 and RP11-778P17/3q11 on 3p of inv(3) in
case 3 (f).
doi:10.1371/journal.pone.0085851.g001
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Processing of Illumina RNA-sequencing Reads
Prepared libraries were sequenced using HiSeq 2000 (Illumina)
operated in paired-end 26100 bp mode. Reads were quality-
filtered using standard Illumina process.
Analysis of RNA-sequencing Data
The fastq files were mapped to the reference human genome
(Human.B37.3) using the Ensembl gene model (Homo_sa-
piens.GRCh37.67). The mapping and downstream analysis were
performed with the software ArrayStudio, version 6.0 [37]. The
mapped reads were used to calculate read counts per gene as well
as fragments per kilobase of exon per million fragments mapped
(FPKM). The read counts were used as input for the application
DEseq [38], specially designed to find differentially expressed
genes in RNA-sequencing data and for comparisons of single
cases. DEseq returns a fold change in expression of every gene as
well as the associated p-value and false discovery rate (FDR). We
performed a pair-wise comparison between every sample express-
ing FOXP1NT and the sample expressing FOXP1FL. Additionally,
we compared all possible combinations of two samples expressing
FOXP1NT versus the sample expressing FOXP1FL. The three
samples expressing FOXP1NT were grouped and also compared
against the sample expressing FOXP1FL. In each comparison, we
selected the genes with FDR lower than 0.2 and uploaded them to
the Ingenuity Pathways Analysis software (IPA, Ingenuity Systems
Inc., Redwood City, CA). In IPA, we retrieved genes that were
common in the individual DEseq tests. The gene sets were used for
an IPA core analysis aimed at identification of affected networks
using only the two highest confident levels (experimentally
observed data or highly predicted interaction). The RNA-
sequencing dataset was also explored to detect somatic mutations.
Only mutations with a frequency of at least 15% were retrieved.
Reads from PCR duplicates and sigletons were not considered in
the frequency calculations. SNP variants from DBSBP137 were
removed and the following categories of mutations were reviewed:
Del 39UTR, Del Non-synonymous, Del-splicing, Non-synony-
mous, Splicing, StopGain, StopLoss. Mutations were annotated
using Polyphen and SIFT prediction algorithms. RNA-sequencing
data are available at GEO (Accession number: GSE50514).
Results
Cytogenetic and FISH Analysis
We collected four B-cell lymphoma cases with the FISH proven
3p13/FOXP1 chromosomal aberrations not involving IG loci
(further referred to as index cases) (Table 1, Figure 1). Two of
them, case 1 with t(2;3)(q36.1;p13) and case 4 with unknown
t(non-IG/FOXP1) detected in cases of MZL and non GCB-
DLBCL, respectively, were previously reported [33,35]. Two
novel aberrations, t(3;10)(p13;q24) and inv(3)(p13q11), were found
respectively in a case of CLL at time of Richter transformation
(case 2) and in a case of progressive MZL (case 3). The 3p13
rearrangements in index cases were initially characterized by
FISH using a set of Bacterial Artificial Chromosome (BAC) clones
spanning FOXP1 (Figure 2, Table S1). In all cases the breakpoints
were mapped in the terminal (coding) region of FOXP1 flanked by
RP11-135M05 and -79P21 spanning exon 6 and exon 8 onwards,
respectively. In contrast, two cases with t(3;14)(p13;q32)/IGH-
FOXP1 (cases 5 and 6) included in this study, revealed the 3p13
breakpoints within the 59 untranslated region of FOXP1 flanked by
RP11-713J07 and -905F6. Of note, two out of 16 cases with
t(FOXP1) studied by Goatly et al. also showed the 3p13 breakpoints
within a coding region of FOXP1 [32].
The reciprocal partner breakpoints of cases 1, 2 and 3 were
investigated by BAC-walking FISH using sets of probes for 2q36,
10q24 and 3p11-3q13, respectively. Detailed results of FISH
analysis are shown in Table S1. Briefly, the 2q36.1 breakpoint of
t(2;3)(q36;p13) (case 1) was mapped in the region spanned by
RP11-183N07 (Figure 1b). Of note, this clone harbors the entire
AP1S3 gene located in an opposite transcriptional orientation to
FOXP1. The 10q24 breakpoint of t(3;10)(p13;q24) (case 2) was
narrowed down to the approximately 40 kb area bordered by
RP11-346A7 and RP11-2F13 (Figure 1d). This small region
harbors three genes: TMEM180, located in the same transcrip-
tional orientation as FOXP1, and C10orf95 and ACTRIA, both
oriented opposite to FOXP1. Notably, the t(3;10)(p13;q24) was
found in one of two cytogenetically related subclones which were
identified at time of a high grade transformation of CLL (Table 1,
2b), but were not detected in a diagnostic sample characterized by
D13q14 (RBI1/D13S319) (Table 1, 2a). Cytogenetic analysis of
case 3 was performed on two diagnostic samples, bone marrow
(BM) (Table 1, 3a) and lymph node (LN) (Table 1, 3b). The former
sample revealed a relatively simple karyotype with t(3;3)(p21;q26)
and del(6)(q23). The karyotype of LN was related but more
complicated. Among others, it displayed secondary rearrange-
ments of one der(3) (later referred to as inv(3)(p13q11) involving
FOXP1 (Figure 1e). The reciprocal breakpoint of inv(3) was
investigated by FISH and eventually mapped in the near-
centromeric region at 3q11 flanked by two consecutive probes:
CTD-2234G15, which stayed at 3p11 and RP11-778P17, the first
available 3q11 probe, which moved to 3p13 (Figure 1f). Notably,
no genes have been mapped to this region of approximately
3.2 Mb annotated as a golden path gap (http://www.ensembl.
org). Given that the 3p13/FOXP1 aberration in case 4 was not
Figure 2. Localization of the 3p13/FOXP1 breakpoints mapped by FISH in cases with t(3;14)(p13;q32) and non-IG rearrangements of
FOXP1. Schematic representation of the genomic structure of FOXP1 is shown in the middle panel and the applied FISH probes are indicated in the
lower panel.
doi:10.1371/journal.pone.0085851.g002
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identified by cytogenetics, further FISH studies of this case were
limited to application of probes flanking the 2q36, 10q24 and 3q11
breakpoints in cases 1, 2, 3, respectively. All these probes,
however, showed a normal hybridization pattern in this case.
Relevant clinical features of the index cases are presented in
Table S3. There were two female and two male patients in age
ranging from 50 to 73 years (on average 63). The patients
developed MZL, CLL and gastric non-GCB-DLBCL. Both MZLs
progressed during follow-up and CLL underwent high grade
transformation (Richter syndrome). Three documented patients
(cases 1–3) died due to lymphoma-related disease after 2.5–26
months (on average 12) after genetic detection of a 3p13/FOXP1
aberration. The appearance of FOXP1 rearrangements during
follow-up (cases 2 and 3) or in a subclone at time of diagnosis (case
4) indicates that non-IG rearrangements of FOXP1 were secondary
hits acquired during the clinical course of disease.
FOXP1 Expression by IHC
All four index cases were subjected to IHC with two monoclonal
anti-FOXP1 antibodies, ab 16645 from Abcam and SP133 from
Roche Diagnostics, both recognizing epitopes located in the C-
terminus of FOXP1 protein. We also analyzed selected positive
controls (cases 5–14), negative controls (cases 15–16) and three
non-malignant (reactive) LN (NL1–3). Examples of IHC are
shown in Figure S1. Neoplastic cells of index cases and positive
controls revealed a nuclear expression of FOXP1 (Table 1). Of
note, gain of FOXP1 tumoral protein expression in case 3
correlated with the acquisition of FOXP1 rearrangement (sample
b). Neoplastic cells of FOXP1-negative DLBCL did not express
FOXP1, but a proportion of non-malignant cells displayed positive
staining. NL1–3 showed FOXP1 positivity in both T- and B-cells
in paracortex and lymphocytic corona, and in a small proportion
of the germinal center B-cells, as previously described [5,6].
FOXP1 Expression by QRT-PCR
To determine expression pattern of FOXP1 transcripts in cases
with non-IG aberrations of FOXP1, we performed QRT-PCR
analysis of two available index cases (cases 3 and 4) using six
primer pairs representing exons 3/4, 5/6, 7/8, 11/12, 14/15 and
17/18 (Table S2). We also included cases with t(3;14)(p13;q32)
(cases 5 and 6), FOXP1-positive lymphomas with no apparent
structural aberrations of the gene (cases 7–14), FOXP1-negative
lymphomas (cases 15 and 16 ) (Table 1), non-malignant lymph
nodes (NL1–3) and the sorted CD19+ B-cells. RPMI-8402, a T-
cell leukemia cell line expressing FOXP1 transcript on low level,
was used as control. The results are summarized in Table 1 and
illustrated in Figure 3. Both index cases and FOXP1-positive
lymphomas (except of case 7) revealed a low expression of exons
3/4 and 5/6 and an increased expression of exons 7/8 and
onwards compared to exons 5/6. Lymphomas with t(3;14)/IGH-
FOXP1 (cases 5 and 6) and case 7 displayed an enhanced
expression of exons 5/6 onwards when compared with exons 3/4.
FOXP1-negative lymphomas showed an enhanced expression of
exons 7/8–17/18 (cases 15 and 16), which likely reflected
expression of FOXP1 by residual non-malignant cells. Among
the non-malignant samples analyzed, the highest expression of
FOXP1 mRNA was detected in the sorted CD19+ B-cells. In these
specimens, all FOXP1 exons analyzed showed enhanced expres-
sion.
59RACE- PCR
To identify putative partner genes of FOXP1 in the index cases,
two available cases (cases 3 and 4) were subjected to 59RACE-
PCR. Following QRT-PCR data, we applied primers for exon 7,
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which was the first commonly upregulated coding exon of FOXP1
in these lymphomas (Figure 3), and expected to identify flanking
upstream sequences. The analysis was also performed on eight
cases of FOXP1-positive DLBCL/MZL (cases 7–14). After
59RACE-PCR and cloning, up to 44 colonies per case were
randomly sequenced. This analysis did not detect any FOXP1
fusion in the index cases, but unexpectedly, identified PLEKHG1
(6q25.1) as a fusion partner of FOXP1 in case 7 (Figure 4). The
fusion, however, occurred out of the reading frame of FOXP1
indicating that the PLEKHG1-FOXP1 rearrangement did not result
in a functional chimeric product. As rearrangements of both genes
were not demonstrated by FISH (Table S1), the fusion was likely
generated by either e.g., a cryptic insertion, or was present in a
minor clone.
Of note, all cases analyzed by 59RACE-PCR revealed
expression of different isoforms of FOXP1 containing exon 7 and
various upstream exons. Particularly frequently expressed was
transcript or transcripts expressing an alternative exon 6b, which
according to Ensembl (Homo_sapiens.GRCh37.67) is shared by
FOXP1-009 and -011. This observation was further confirmed by
QRT-PCR, which detected a common expression of exon 6b-
positive transcripts in the cases analyzed (data not shown).
Western Blot Analysis
Eight cases with available material (cases 3, 5–7, 12, 13, 15 and
16) and three non-malignant LNs were subjected to Western blot
analysis with the monoclonal JC12 antibody. As shown in
Figure 5a, at least four bands with a differential expression were
detected in the samples analyzed: the 75 kDa band corresponding
to the FOXP1FL protein and bands of 64, 60 and approximately
45 kDa. The 75 kDa band was predominantly expressed in both
cases with t(3;14)(p13;q32) (cases 5 and 6) and in three non-
malignant LNs. The index case and three FOXP1-positive
DLBCLs (cases 7, 12 and 13) showed a marked expression of 64
and 60 kDa isoforms, and a various expression of band of 75 kDa.
Case 7 revealed additional bands of 45 kDa and 70–73 kDa, not
Figure 3. QRT-PCR analysis of FOXP1 mRNA expression. Examples of QRT-PCR analysis performed in cases with non-IG aberration of FOXP1
(cases 3), t(3;14)(p13;q32)/IGH-FOXP1 (case 5), FOXP1-positive DLBCL without FOXP1 rearrangements (case 8), FOXP1-negative DLBCL (case 16), non-
malignant lymph node (NL1) and sorted CD19+ B cells. RPM1-8402, T-ALL cell line expressing FOXP1 transcript on low level was used as control. The
analyzed exons are marked in the right side of the panel.
doi:10.1371/journal.pone.0085851.g003
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expressed in the remaining cases. Whether the latter band
represents a processed full-length protein or another isoform is
unknown. FOXP1-negative DLBCLs (cases 15 and 16) displayed a
weak expression of 75 and/or 64/60 kDa proteins.
To evaluate a relative abundance of the full length protein and
shorter isoforms in the cases analyzed, we performed at first a
densitometric analysis of expressed isoforms (Table S4). Then, we
merged densitometric values of all three shorter proteins (64/60/
45) and compared them with expression of the 75 kDa protein.
Results presented in Figure 5b confirmed a predominant
expression of the full length protein in both cases with
t(3;14)(p13q32) (cases 5 and 6) and in all three non-malignant
LNs, and pointed a significantly higher expression of shorter
isoforms in case 3 and two of three FOXP1-positive DLBCL cases
(cases 12 and 13). The exceptional case 7 displayed an abundant
expression of the 75 (70–75?) kDa protein.
RNA-sequencing Analysis
RNA-sequencing of six FOXP1-expressing lymphomas, which
included three cases with FOXP1 rearrangements (case 3 with
inv(3), case 5 with t(3;14)(p13;q32) and case 7 with PLEKHG1-
FOXP1), and three cases with no apparent structural aberrations of
FOXP1 (cases 8, 11 and 12) was performed. In addition, two
FOXP1-negative DLBCLs (cases 15 and 16) were also included.
The total number of reads produced by sequencing for each
sample ranged from 87134076 to 115622676 with a median of
94596970. The percentage of uniquely mapped paired reads
ranged from 81 to 90% with a median of 89%. RNA-sequencing
detected FOXP1 transcripts in all cases analyzed, but two FOXP1-
negative lymphoma cases showed a significantly lower overall
expression of FOXP1 transcripts than FOXP1-positive tumors (on
average 486.3 FPKM vs 1190.9 FPKM) (Figure S2). RNA-
sequencing data were initially used to verify IHC subtyping of
seven DLBCL cases. We analyzed expression values of the
predictor genes reported by Wright et al. [39] to classify DLBCLs
into ABC/non-GCB and GCB subtypes. Principal component
analysis and hierarchical clustering showed that all six non-GCB-
DLBCL cases clustered together and were distinct from the GCB-
DLBCL case 15 (Figure S3). Further analysis of potential chimeric
transcripts did not detect any fusion of FOXP1, including
Figure 4. Characterization of the PLEKHG1/FOXP1 fusion. (a) Schematic representation of the PLEKHG1-FOXP1 fusion identified by 59-RACE PCR
in case of FOXP1-positive DLBCL (case 7). Sequence analysis showed a fusion between an approximately 270 bp 59 fragment of PLEKHG1 (breakpoint
in the intronic region between exon 1 and 2) and exon 7 of FOXP1. (b) Fusion transcript was confirmed by RT- PCR using reverse primer on exon 7 of
FOXP1 and two forward primers (P1 and P2) on PLEKHG1.
doi:10.1371/journal.pone.0085851.g004
Figure 5. Proteosomic analysis of FOXP1. (A) Results of Western blotting with a monoclonal JC12 antibody performed in the index case 3 with
inv(3), two cases with t(3;14)(p13;q32) (cases 5 and 6), case 7 with PLEKHG1-FOXP1, two cases of FOXP1-positive DLBCL without FOXP1
rearrangements (cases 12 and 13), two cases of FOXP1-negative DLBCL (cases 15–16) and three non-malignant LNs (NL1–3). Anti-beta-actine antibody
was used for loading control. (B) Relative abundance of the full-length FOXP1 protein (75 kDa) and three shorter proteins with molecular weight of
64/60/45 kDa, based on merged protein densitometric values.
doi:10.1371/journal.pone.0085851.g005
FOXP1 Aberrations in Lymphoid Neoplasms
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e85851
PLEKHG1-FOXP1 previously identified in case 7 by 59RACE-
PCR. This finding suggests that the fusion occurred in a minor
clone. Mutation analysis identified a wide range of mutations in all
analyzed lymphomas, but none targeted FOXP1. Of interest, non-
synonymous mutations of two known DLBCL-related genes,
MYD88 and CARD11 [40,41], were detected in 3 cases (no. 3, 7
and 12) and one case (no. 12), respectively (data not shown).
Looking for unique mutations in case 5 expressing FOXP1FL, we
found eight genes (excluding IGLV) affected by non-synonymous
mutations and 32 genes with Del39UTR (Table S5) Notably, KLF5
was affected by two mutations, S236C and S237, both predicted as
deleterious by Polyphen 2 algorithm. IPA analysis of the genes
uniquely mutated in case 5 revealed a network of interactions
(mostly direct interactions) with several cancer genes including
MYC, TP53, BCL2, PI3K and NFkBIA (Figure S4).
To get insights into transcriptional networks regulated by
FOXP1NT, we ran inference analyses comparing transcriptomes of
cases 8, 11 and 12 expressing FOXP1NT with the transcriptome of
case 5 expressing FOXP1FL, all diagnosed as non-GCB-DLBCL
(see Material and Methods). Cases 3 and 7 were excluded from the
inference analysis due to lack of an equivalent control sample in
the former case, and complex proteomic pattern of the latter case
(Figure 5a). Given a weak expression of short FOXP1 isoforms in
case 16 (Figure 5c), this sample was not used as a negative control.
IPA analysis of the datasets obtained identified 112 genes
commonly dysregulated (downregulated) in all seven inference
analysis performed (Table S6). The IPA core analysis of these
genes identified three top networks comprising 36, 23 and 21
genes, respectively (Table S7). Top diseases and functions of the
second most significantly dysregulated network are ‘‘Cell Death
and Survival, Cellular Movement, Cancer’’. This network,
including FOXP1, is shown in Figure 6. It comprises at least three
key cancer genes, TP53, CDKN1A and MYC, recently shown to
repress microRNA-34a which regulates expression of FOXP1 [42].
Of note, SERPINB5 (maspin) found to be significantly downreg-
ulated in cases 8, 11 and 12 versus case 5, is a candidate tumor
suppressor in prostate cancer [43]. HIP1R, a postulated target of
FOXP1 in ABC-DLBCL was not consistently downregulated in
FOXP1NT-positive DLBCLs. We cannot exclude, however, that
other accessory proteins also contribute to FOXP1 repression of
HIP1R, as previously argued [44].
Discussion
The work presented here was inspired by our previous finding
of the novel FOXP1-related t(2;3)(q36;p13) in case of MZL [35]. In
contrast to t(3;14)(p13;q32)/IGH-FOXP1 affecting the 59 untrans-
lated region of FOXP1 [31,34], the 3p13 breakpoint of
t(2;3)(q36;p13) was mapped within the coding domain of the
gene. Given that MALT1, another oncogene implicated in the
Figure 6. Interaction network of genes differentially expressed by three FOXP1NT-positive DLBCLs when compared with case 5
expressing FOXP1FL with the important cancer genes found by IPA. Continuous and discontinuous lines indicate direct and indirect
interactions, respectively. Note that all differentially genes are dysregulated (marked in green). The intensity of the green color reflects the expression
level (more intense= lower fold change).
doi:10.1371/journal.pone.0085851.g006
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pathogenesis of MZL, is involved in two types of translocations,
t(14;18)(q32;q21)/IGH-MALT1 [45,46] and t(11;18)(q21;q21) gen-
erating the API2(BIRC3)-MALT1 chimeric gene [47,48], we
initially hypothesized that t(2;3)(q36;p13) encodes a FOXP1-related
fusion transcript [35]. However, the subsequent discovery of a
predominant expression of shorter FOXP1 isoforms by FOXP1-
positive ABC-DLBCL led to the hypothesis that 3p13 transloca-
tions targeting the coding region of FOXP1, like t(2;3)(q36;p13),
may activate expression of N-terminally truncated isoform(s) of
FOXP1 [28,32]. To validate this interesting concept and to
decipher the molecular consequences of non-IG aberrations of
FOXP1 in general, we performed comprehensive genetic and
molecular investigations of four lymphoma cases with non-IG
rearrangements of FOXP1 and compared these with cases
harboring t(3;14)(p13;q32)/IGH-FOXP1 and FOXP1-positive
DLBCL with no apparent structural aberrations of the gene.
Our study demonstrated that FOXP1 breakpoints in all index cases
fall within the coding region of FOXP1 and unlike the
t(3;14)(p13;q32) do not locate to the 59untranslated region of the
gene. We also found that non-IG aberrations of FOXP1
promiscuously affect partner sequences at various chromosomal
regions (2q26, 3q11, 10q24 and other) targeting either a gene-poor
region or gene that is in the incorrect transcriptional orientation to
be fused with FOXP1. Therefore these aberrations do not
generate functional chimera products. Even the PLEKHG1-FOXP1
fusion identified in case 7 was not functional because it occurred
out of the reading frame of FOXP1. To prove that the disruption of
the FOXP1 coding sequences by these aberrations activates
expression of short FOXP1 isoforms, we performed preliminary
transcriptomic and proteosomic investigations of a few available
cases. Using QRT-PCR, we showed that the index cases
abundantly express sequences encoded by exon 7 onwards, but
not by all coding exons of FOXP1 (exon 6 onwards). This finding is
in line with their 3p13 breakpoints positioned between exon 6 and
8 of FOXP1. A similar pattern of FOXP1 expression was detected
in FOXP1-positive DLBCL without rearrangements of the gene,
confirming the previously published data [28]. In contrast, cases
with t(3;14)/IGH-FOXP1 which affects the 59untranslated region
of FOXP1 expressed all coding exons of the gene. Further evidence
was provided by Western blotting which in general, detected three
differently expressed FOXP1 isoforms: of 75 kDa, representing
FOXP1FL, and of 64 and 60 kDa, representing shorter FOXP1
isoforms. Notably, the 75 kDa molecule was highly and predom-
inantly expressed in both lymphomas with t(3;14)(p13;q32) and in
non-malignant LNs, while the 64 and 60 kDa isoforms were
predominantly expressed in FOXP1-positive DLBCLs without
FOXP1 rearrangements (Figure 5a). Case 3, the only one case with
a non-IG aberration of FOXP1 analyzed, showed a predominant
expression of both shorter isoforms as well as a significant
expression of protein of 75 kDa. The latter band, however, may
represent isoform FOXP1-011 with a molecular weight of 76 kDa,
thus indistinguishable from FOXP1FL. This assumption is
supported by the QRT-PCR data showing preferential expression
of exon 7 onwards and the 59RACE-PCR which detected a strong
expression of transcript variant(s) with an alternative exon 6b
which features FOXP1-011 (www.ensembl.org). Generally, our
findings are in line with observations of Brown et al. [28], who
were the first to demonstrate expression of shorter FOXP1
isoforms (60–65 kDa) in ABC-DLBCL cell lines and primary
lymphomas. Identification of the abundantly expressed isoforms,
however, is challenging. The 64 kDa band may represent FOXP1-
009 (573 aa/64 kDa) which also contains the alternative exon 6b.
Ensembl (Homo_sapiens.GRCh37.67), however, does not anno-
tate any isoform of 60 kDa. Further investigations are warranted
to clarify whether 64 and 60 kDa bands represent the same
isoform which underwent posttranslational modifications, or two
different isoforms of FOXP1.
Altogether, our findings support the hypothesis that non-IG
aberrations affecting the coding region of FOXP1 activate an
aberrant expression of the 59end-truncated variant transcripts of
FOXP1. The molecular mechanisms underlying these lesions,
however, remain largely unknown. As promoter substitution
cannot be the common mechanism operating in these cases, we
assume that non-IG rearrangements could either activate alterna-
tive internal promoter(s) of FOXP1 (http://www.humangenes.org)
or lead to loss of negative regulatory elements, similar like
activating rearrangements of LMO2 in T-ALL [49]. Interestingly,
an alternative mechanism of generation of N-terminal deletion of
foxp1 was reported in myeloblastosis-associated virus type-2-
induced chicken nephroblastoma [50]. This oncogenic isoform
was induced by a retroviral integration in the second coding exon
of foxp1, which corresponds to exon 7 of FOXP1, targeted by non-
IG aberrations in human lymphoma. Activation of truncated
oncoproteins by chromosomal translocations has been previously
described in cancer, including B-ALL and prostate tumors
harboring promiscuous translocations of PAX5 [51,52] and
ETV1 [53], respectively. Molecular pathways affected by
FOXP1NT in lymphoma are largely unknown. Recent studies of
Wong et al. [44], however, identified HIP1R as a potential target
of FOXP1 in ABC-DLBCL, and ChIP-on-chip analysis of the
human GC-like DLBCL cell line OCI-Ly1 reported by Sagardoy
et al. [5] identified 279 FOXP1 target genes. IPA analysis of our
RNA-sequencing expression data of 4 non-GCB-DLBCL cases
detected a set of dysregulated genes in three cases expressing
FOXP1NT when compared with the case expressing FOXP1FL.
These genes, which were exclusively downregulated and code for
cytoplasmic, membrane and extracellular molecules, were found
to be directly linked to MYC and other key cancer genes. They
may comprise direct or non-direct targets of FOXP1NT,
potentially implicated in disease progression. Their identification,
however, requires further molecular studies performed on large
series of FOXP1-positive lymphomas.
Collectively, we provide evidence that FOXP1 is the target of
two molecularly distinct types of rearrangements in B-cell
neoplasms: (i) t(3;14)(p13;q32)/IGH-FOXP1, which dysregulates
expression of FOXP1FL, and (ii) non-IG aberrations, which result
in ectopic expression of FOXP1NT. The former translocation is
regarded as the primary genetic event, because like other well-
known IGH-mediated translocations in B-cell lymphoma, it occurs
as a sole karyotypic aberration and is present in diagnostic
samples. Consequently, the aberrantly expressed FOXP1FL seems
to play an oncogenic role in lymphoma. In contrast, non-IG
rearrangements of FOXP1 are found as secondary genetic hits
acquired during clinical course of various B-cell neoplasms
(DLBCL, MZL and CLL), frequently heralding inferior outcome.
Therefore, the overexpressed FOXP1NT isoforms seem to be
implicated in disease progression. Our new finding of the
FOXP1NT involvement in high grade transformation of CLL
remains in line with the data recently published by Quesada et al.
[54]. This group identified a novel C-terminally truncated FOXP1
protein aberrantly expressed in CLL and showed that this isoform
is generated by mutated SF3B1 (splicing factor 3b, subunit 1).
Mutations of SF3B1 were found in 9.7% of CLLs analyzed by
whole-exome sequencing and were associated with an advanced
disease at diagnosis and poor overall survival of affected
individuals.
Although our study postulates the oncogenic role of FOXP1FL
in lymphomagenesis, constitutive expression of FOXP1FL in
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transgenic mice seems to be insufficient to drive tumorigenes [5].
Therefore, we presume that FOXP1, like BCL2 [55,56], may
require additional genetic hits to initiate lymphoma. To identify
such hit(s), we searched for unique mutations in case 5 with
t(3;14)/qFOXP1FL. Among approximately 40 mutated genes,
one gene, KLF5, was targeted by two potentially deleterious
mutations. Thus far, the implication of KLF5 in lymphomagenesis
is unknown, but this transcription factor is involved in several
important biological processes including cell proliferation, trans-
formation, hematopoietic stem cell homing and carcinogenesis
[57–59].
Altogether, our data support the important role of FOXP1-
associated rearrangements in development and progression of B-
cell lymphoma. Further studies, however, are needed to decipher
complexity of FOXP1 and presumably opposing roles of the gene
in the pathogenesis of lymphoid and epithelial tumors.
Supporting Information
Figure S1 Morphology and FOXP1 expression detected
by IHC with SP133 antibody in index and control cases.
(A–B) Case 3 with inv(3): polymorphic marginal zone lymphoma
showing a strong nuclear FOXP1 expression in the neoplastic
cells. (C–D) Case 5 with t(3;14)(p13;q32)/IGH-FOXP1: non-GCB-
DLBCL showing a strong nuclear FOXP1 expression in the
neoplastic cells. (E–F) Case 8: non-GCB-DLBCL without FOXP1
rearrangement showing a strong nuclear FOXP1 expression in the
neoplastic cells. (G–H) Case 15: GCB-DLBCL negative for
FOXP1 immunostaining. (I–J) NL1: reactive follicular hyperplasia
with selective FOXP1 expression in both T- and B- cells in
paracortex and lymphocytic corona, and in a small fraction of GC
cells. Scale bar: 50 um.
(JPG)
Figure S2 Expression of FOXP1 determined by RNA-
sequencing.
(TIF)
Figure S3 Performance of GC and non-GCB subgroup-
ing of DLBCL cases subjected to RNA-seq using
expression values of predictor genes described by
Wright et al. [39].
(PPTX)
Figure S4 Interaction network of genes exclusively
mutated in t(3;14)-positive case 5 (in grey) with the well
know cancer genes specified by IPA. Continuous and
discontinues lines indicate direct and indirect interactions,
respectively. Red arrows mark genes found to be upregulated in
FOXP1FL expressing case 5 when compared with cases expressing
FOXP1NT.
(PPTX)
Table S1 Results of FISH analysis.
(XLSX)
Table S2 List of the primers.
(XLSX)
Table S3 Relevant clinical features of the index cases.
(XLSX)
Table S4 Densitometric measurements of WB bands.
(XLSX)
Table S5 List of mutated genes in cases 5 with t(3;14)/
IGH-FOXP1.
(XLSX)
Table S6 List of commonly dysregulated genes in
FOXP1NT-expressing non-GCB-DLBCLs when compared
with case 5 expressing FOXP1FL.
(XLS)
Table S7 Top networks, diseases and functions of genes
dysregulated by FOXP1NT-expressing non-GCB-DLBCLs
when compared with case 5 expressing FOXP1FL
specified by IPA. The dysregulated (downregulated) genes are
in bold type.
(PDF)
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